Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer

被引:1
作者
Skoeld, Camilla [1 ]
Corvigno, Sara [2 ]
Dahlstrand, Hanna [2 ]
Enblad, Gunilla [1 ]
Mezheyeuski, Artur [3 ]
Sundstroem-Poromaa, Inger [4 ]
Stalberg, Karin [4 ]
Tolf, Anna [1 ]
Glimelius, Ingrid [1 ,5 ]
Koliadi, Anthoula [1 ]
机构
[1] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden
[2] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[3] Vall dHebron Inst Oncol, Barcelona, Spain
[4] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden
[5] Karolinska Inst, Dept Med, Div Clin Epidemiol, Stockholm, Sweden
关键词
Ovarian cancer; Parity; Progesterone receptor; Tissue micro array; HORMONE-RECEPTOR EXPRESSION; RISK-FACTORS; PROGESTERONE; ESTROGEN; EPITHELIUM; APOPTOSIS; OVULATION; SURVIVAL;
D O I
10.1007/s10552-024-01876-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose High-grade serous ovarian cancer (HGSC) is the most common ovarian cancer subtype. Parity is an important risk-reducing factor, but the underlying mechanism behind the protective effect is unclear. Our aim was to study if the expression of hormones and proteins involved in pregnancy were affected by the woman's parity status, and if they may be associated with tumor stage and survival.Methods We evaluated expression of progesterone receptor (PR), progesterone receptor membrane component 1 (PGRMC1), relaxin-2, and transforming growth factor beta 1 (TGF beta 1) in tumor tissue from 92 women with HGSC parous (n = 73) and nulliparous (n = 19). Key findings were then evaluated in an independent expansion cohort of 49 patients. Survival rates by hormone/protein expression were illustrated using the Kaplan-Meier method. The independent prognostic value was tested by Cox regression, using models adjusted for established poor-prognostic factors (age at diagnosis, FIGO stage, type of surgery, and macroscopic residual tumor after surgery).Results HGSC tumors from parous women were PR positive (>= 1% PR expression in tumor cells) more often than tumors from nulliparous women (42% vs. 16%; p-value 0.04), and having more children was associated with developing PR positive tumors [i.e., >= 3 children versus nulliparity, adjusted for age at diagnosis and stage: OR 4.31 (95% CI 1.12-19.69)]. A similar result was seen in the expansion cohort. Parity status had no impact on expression of PGRMC1, relaxin-2 and TGF beta 1. No associations were seen with tumor stage or survival.Conclusion Tumors from parous women with HGSC expressed PR more often than tumors from nulliparous women, indicating that pregnancies might possibly have a long-lasting impact on ovarian cancer development.
引用
收藏
页码:1101 / 1109
页数:9
相关论文
共 50 条
  • [41] Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma
    Stewart, L. M.
    Stewart, C. J. R.
    Spilsbury, K.
    Cohen, P. A.
    Jordan, S.
    GYNECOLOGIC ONCOLOGY, 2020, 156 (03) : 611 - 615
  • [42] The Emerging Role of the Single-Cell and Spatial Tumor Microenvironment in High-Grade Serous Ovarian Cancer
    Launonen, Inga-Maria
    Vaharautio, Anna
    Farkkilae, Anniina
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2023, 13 (10):
  • [43] Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
    Boyarskikh, Ulyana A.
    Gulyaeva, L. F.
    Avdalyan, A. M.
    Kechin, A. A.
    Khrapov, E. A.
    Lazareva, D. G.
    Kushlinskii, N. E.
    Melkonyan, A.
    Arakelyan, A.
    Filipenko, Maxim Leonidovich
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [44] Nomograms to Predict the Density of Tumor-Infiltrating Lymphocytes in Patients With High-Grade Serous Ovarian Cancer
    Dai, Danian
    Liu, Lili
    Huang, He
    Chen, Shangqiu
    Chen, Bo
    Cao, Junya
    Luo, Xiaolin
    Wang, Feng
    Luo, Rongzhen
    Liu, Jihong
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [45] Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics
    Madeddu, Clelia
    Lai, Eleonora
    Neri, Manuela
    Sanna, Elisabetta
    Gramignano, Giulia
    Nemolato, Sonia
    Scartozzi, Mario
    Giglio, Sabrina
    Maccio, Antonio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (05)
  • [46] Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma
    Santillan, A.
    Kim, Y. W.
    Zahurak, M. L.
    Gardner, G. J.
    Giuntoli, R. L., II
    Shih, I. M.
    Bristow, R. E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (03) : 601 - 606
  • [47] Spatiotemporal architecture of immune cells and cancer-associated fibroblasts in high-grade serous ovarian carcinoma
    Xu, Alexander M.
    Haro, Marcela
    Walts, Ann E.
    Hu, Ye
    John, Joshi
    Karlan, Beth Y.
    Merchant, Akil
    Orsulic, Sandra
    SCIENCE ADVANCES, 2024, 10 (16)
  • [48] Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting
    Liontos, Michalis
    Papatheodoridi, Alkistis
    Andrikopoulou, Angeliki
    Thomakos, Nikolaus
    Haidopoulos, Dimitrios
    Rodolakis, Alexandros
    Zagouri, Flora
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    CURRENT ONCOLOGY, 2021, 28 (02) : 1143 - 1152
  • [49] The preoperative prognostic nutritional index is a predictive and prognostic factor of high-grade serous ovarian cancer
    Feng, Zheng
    Wen, Hao
    Ju, Xingzhu
    Bi, Rui
    Chen, Xiaojun
    Yang, Wentao
    Wu, Xiaohua
    BMC CANCER, 2018, 18
  • [50] Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer
    Tan, Jiahong
    Song, Chunyan
    Wang, Daoqi
    Hu, Yigang
    Liu, Dan
    Ma, Ding
    Gao, Qinglei
    BIOSCIENCE REPORTS, 2021, 41 (05)